Business Update27 Mar 2024, 04:03 pm
Caplin Point Laboratories Completes State-of-the-art Oncology Facility, Commences Operations
AI Summary
Caplin Point Laboratories' subsidiary, Caplin One Labs Limited, has completed its state-of-the-art Oncology facility at Kakkalur, near Chennai, and commenced operations. The Rs. 150 Crores investment has enabled the unit to initially manufacture Oral Solid Dosage Oncology products and later expand its portfolio to over 50 oncology products. Initially, the products will be targeted at Latin American countries, with medium-term plans for market entry into regulated markets such as US, EU, Mexico, and others.
Key Highlights
- Completion and commencement of operations of a new state-of-the-art Oncology facility by Caplin One Labs Limited.
- An investment of Rs. 150 Crores for manufacturing Oral Solid Dosage Oncology products and expanding the portfolio to over 50 oncology products.
- Initial focus on Latin American markets, with plans to launch in regulated markets such as US, EU, Mexico, and others.
- Expected compliance with US FDA standards from the outset for swift market entry.
- Committed to delivering superior pharmaceutical products and increasing market footprint in the oncology business